Serous Cystic Neoplasms of the Pancreas: a Clinicopathologic and Immunohistochemical Analysis [this Article Has Been Retracted]

Yuan JI,Xiu Nan WANG,Wen Hui LOU,Akesu SUJIE,Yun Shan TAN,Da Yong JIN
DOI: https://doi.org/10.1111/j.1443-9573.2006.00242.x
2006-01-01
Chinese Journal of Digestive Diseases
Abstract:OBJECTIVE: To clarify whether the various subtypes of serous cystic neoplasms (SCNs) of the pancreas can be distinguished from each other by marker profiles.METHODS: The immunoprofiles of 13 SCNs were defined by using antibodies against cytoskeletal, neuroendocrine, hormone receptor, and mucin markers. In addition, we examined the expression of calrentinin and alpha‐inhibin.RESULTS: SCN included 7 cases of serous microcystic adenomas (SMA), 3 cases of serous oligocystic ill‐defined adenomas (SOIA), 1 case of solid serous adenoma (SSA), 1 case of von Hippel‐Lindau‐associated cystic neoplasm (VHL‐CN), and 1 case of serous cystadenocarcinoma (SCC). These neoplasms are histologically similar, but differ in their localization, gross appearance, gender distribution, and biological behavior. The various types of SCNs showed a very similar immunoprofile, characterized by positivity for cytokeratins (100%) and negativity for vimentin and synaptophysin. Other markers that were commonly expressed in the SCNs were alpha‐inhibin (85%), MUC1 (69%) and MUC6 (77%).CONCLUSION: The results suggest that, despite their biologic differences, the various types of SCNs have the same (or a very similar) cell type and may therefore have a common direction of differentiation. A centroacinar origin is supported by the finding that a number of SCNs share MUC1 and MUC6 expression with pancreatic centroacinar cells. Alpha‐inhibin, and MUC6 may be regarded as new markers for this type of pancreatic tumor.
What problem does this paper attempt to address?